이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Unravelling the Effects of Nicotinamide/Pyrroloquinolone Quinone /Citicoline/Homotaurine Fixed Combination on Contrast Sensitivity, Quality of Life, and Reading Performance in Glaucoma

2026년 10월 2일 업데이트: Luca Agnifili, Università degli Studi 'G. d'Annunzio' Chieti e Pescara

Glaucoma is a chronic, progressive neuro-ophthalmic condition that leads to irreversible loss of retinal ganglion cells (RGCs) and is the second leading cause of blindness worldwide. It is associated with elevated intraocular pressure (IOP), but many patients continue to experience vision loss even with controlled IOP. Mitochondrial dysfunction is a key mechanism in RGC damage, leading to interest in neuroprotective treatments. Various compounds like citicoline (CIT), homotaurine (HOMO), vitamin B3 (nicotinamide), and pyrroloquinoline quinone (PQQ) have shown potential in protecting RGCs, improving mitochondrial function, and reducing oxidative stress. This study aims to compare the effects of a combination supplement (NEUPROZIN MITO) containing CIT, HOMO, NAM, and PQQ with CIT alone (OPTIGEN) on contrast sensitivity, quality of life, and reading speed in patients with primary open-angle glaucoma (POAG) and controlled IOP. The study is a randomized, cross-over trial with two treatment groups, and outcomes will include changes in visual function, quality of life, and reading performance over 8 months. The sample size calculation suggests enrolling 44 patients to detect a clinically significant difference. This research will assess the effectiveness of mitochondrial-targeted therapies for glaucoma patients with controlled IOP.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

Glaucoma is a chronic, progressive neuro-ophthalmic disease with a multifactorial basis, leading to irreversible retinal ganglion cell (RGC) loss. It is the second leading cause of blindness globally, and the primary cause of irreversible blindness, affecting 76 million people worldwide in 2020. This number is expected to rise to approximately 120 million by 2040, particularly in Africa and Asia. Elevated intraocular pressure (IOP) is one of the most important risk factors for the development and progression of glaucoma, and its reduction is the only scientifically proven approach to slowing visual function decline. However, despite lowering IOP, many glaucoma patients continue to experience progressive visual loss, even with IOP in the normal range. This is because glaucoma is a multifactorial disease, and reducing IOP alone does not address the other factors damaging the RGCs. Mitochondrial dysfunction appears to be one of the key and early mechanisms involved in RGC damage and death in glaucoma, prompting researchers to consider glaucoma, at least partially, as a specific form of mitochondrial disease. Consequently, there is a significant unmet need for direct neuroprotective therapies alongside IOP reduction.

Several molecules with neuroprotective properties have been identified, including citicoline (CIT), homotaurine (HOMO), vitamin B3 (nicotinamide or nicotinamide riboside), and pyrroloquinoline quinone (PQQ). CIT, which provides choline and cytidine, plays a role in neuronal membrane repair and regeneration. Studies have shown CIT's positive effects on retinal and visual pathway functions. HOMO is a naturally occurring amino sulfonate compound with neuromodulatory and neuroprotective effects. It can prevent amyloid plaque formation in RGCs and modulate cortical activity, reducing neuronal excitatory responses to glutamate, which contributes to RGC death. Vitamin B3 compounds like nicotinamide (NAM) and nicotinamide riboside (NR) are precursors to nicotinamide adenine dinucleotide (NAD), a crucial cofactor in energy production and mitochondrial function. NAD deficiencies are associated with RGC degeneration in glaucoma, and supplementing NAD precursors has shown promise in preventing or delaying cell death. PQQ, a redox cofactor, stimulates new mitochondria formation, activates mitochondrial DNA repair, and serves as a potent antioxidant, protecting cells from oxidative damage.

Recent evidence suggests that combining these mitochondrial-targeted compounds may offer synergistic neuroprotective effects, potentially benefiting RGCs.The study aims to evaluate the effects of an oral combination of NAM (54 mg), PQQ (5 mg), CIT (500 mg), and HOMO (50 mg) (NEUPROZIN MITO) compared to CIT alone (500 mg, OPTIGEN) on contrast sensitivity, quality of life, and reading speed in patients with primary open-angle glaucoma (POAG) and controlled IOP.This is a prospective, randomized, cross-over, monocentric study. Inclusion Criteria: Patients aged over 18, with a good understanding of the Italian language and the ability to read, diagnosed with early to moderate Primary Open-Angle Glaucoma (POAG) (Mean Deviation [MD] > -12 dB). The patients must have intraocular pressure (IOP) controlled (the mean of 3 measurements < 18 mmHg) and stable perimetry results over the past year. Exclusion Criteria: Patients who are illiterate, have severe glaucoma, have undergone ocular surgery within the past 6 months, have significant cataracts, other ocular diseases, neurodegenerative disorders, psychiatric disorders, or are pregnant or breastfeeding. Participants will be randomly assigned to receive either NEUPROZIN MITO or OPTIGEN for the first 4 months. After 4 months, participants will switch to the alternative treatment for the subsequent 4 months. Primary Outcomes: 1) Changes in contrast sensitivity: The ability to detect differences in contrast at 4 and 8 months. 2) Quality of life: Evaluated by the Glaucoma Quality of Life (GQL-15) questionnaire, comparing changes at 4 and 8 months. 3) Reading speed: Measured using the MNREAD test, comparing reading performance at 4 and 8 months. Secondary Outcomes: 1) Differences in response based on disease stage: The study will assess whether the stage of glaucoma affects the response to treatment. 2) Correlation between changes in the parameters: Examining if changes in contrast sensitivity, quality of life, and reading speed are related to one another over the study period. Sample Size Calculation: The study is designed as a cross-over trial, with half of the patients receiving NEUPROZIN MITO followed by OPTIGEN, and the other half receiving OPTIGEN followed by NEUPROZIN MITO. Based on the expected changes in the GQL-15 score and other parameters, the sample size calculation estimates that 44 patients are needed to ensure sufficient statistical power. This number accounts for a 10% dropout rate. Study Procedures: 1) Quality of Life Evaluation: The GQL-15 questionnaire is used to assess functional disability in daily activities. A normal score is between 0 and 75, with higher scores indicating a poorer quality of life. 2) Complete Ophthalmologic Evaluation: Participants will undergo best corrected visual acuity tests, Goldmann tonometry, gonioscopy, and a slit-lamp examination. 3) Functional Stage Determination: The stage of glaucoma will be assessed using automated perimetry (Mean Deviation [MD], Visual Field Index [VFI], Pattern Standard Deviation [PSD], and Glaucoma Hemifield Test [GHT]) and Optical Coherence Tomography (OCT) to measure optic nerve fiber thickness and the ganglion cell layer. 4) SPARCS Test: This is a contrast sensitivity test used to evaluate central and peripheral vision, with a contrast range from 100% to 0.45%. The test is performed on a computer screen, and the patient's ability to discern different contrast levels is evaluated. 5) Reading Speed: Reading speed will be assessed using the MNREAD test app, which measures the time taken to read sentences of decreasing font size. This test helps calculate the patient's reading speed and visual acuity based on text size and reading errors. Main Outcomes: The primary goal of the study is to assess if NEUPROZIN MITO and OPTIGEN induce changes in contrast sensitivity, quality of life, and reading speed in patients with pharmacologically controlled POAG. The results will be compared at 4 and 8 months to evaluate the effectiveness of each treatment. Secondary Outcomes: The study will also evaluate if the response to treatment varies depending on the stage of glaucoma and whether there is any significant correlation between the changes in the parameters measured (contrast sensitivity, quality of life, and reading speed). Conclusion: This study aims to provide crucial data on the potential neuroprotective benefits of mitochondrial-targeted therapies in glaucoma patients with controlled intraocular pressure (IOP). The effects of NEUPROZIN MITO and OPTIGEN on functional outcomes, such as contrast sensitivity, quality of life, and reading speed, will help to better understand how these therapies might impact the management of glaucoma.

연구 유형

중재적

등록 (실제)

44

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Italy
      • Chieti, Italy, 이탈리아
        • Clinica Oftalmologica - Ospedale clinicizzato SS Annunziata di Chieti

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age over 18 years
  • Good knowledge of the Italian language and good reading skills
  • Manifest primary open-angle glaucoma (POAG) in the early to moderate stage (MD > -12 dB). The stage of glaucoma is determined by measuring the mean defect (MD, dB) using standard automated perimetry (HFA II/III; Carl Zeiss Meditec, Dublin, CA, USA, program 24/2).
  • Patients able to provide written informed consent
  • Pharmacologically controlled IOP: average values of 3 measurements (9 AM) <18 mmHg
  • Stable perimetry in the year prior to enrollment

Exclusion Criteria:

  • Illiteracy
  • Severe-stage glaucoma (MD < -12 dB)
  • Previous surgical treatment for glaucoma or other ocular surgeries (except for cataract surgery performed more than 6 months earlier)
  • Concomitant ocular diseases, previous ocular trauma, or high myopia
  • Neurodegenerative diseases of the central nervous system, dysarthria, dyslexia, psychiatric disorders
  • Pregnancy/breastfeeding

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Patients treated with Neuprozin Mito for 4 months followed by 4 months of Optigen

Patients with stable mild to moderate glaucoma, as assessed perimetrically and tonometrically, will be administered Neuprozin Mito for 4 months. After this period, Neuprozin Mito will be discontinued, and patients will be administered Optigen for an additional 4 months. At baseline, 4 months, and 8 months, the following assessments will be performed: best corrected visual acuity (VA) for both distance and near, IOP, 24-2 visual field (Humphrey Field Analyzer (HFA), Zeiss) with determination of MD, PSD, VFI, GHT; OCT to study the peripapillary retinal nerve fiber layer (RNFL) thickness and the macular ganglion cell complex (GCL-IPL) thickness (Cirrus 6000, Carl Zeiss Meditec); contrast sensitivity using the Spaeth/Richman contrast sensitivity (SPARCS) test (on computer support); quality of life assessment using the Glaucoma Quality of Life 15 (GQL-15) questionnaire; and reading performance using the Italian version of the MNREAD test.

one citicoline tablet per day for 4 months

one fixed combination tablet per 4 months

활성 비교기: Patients treated with Optigen for 4 months followed by 4 months of Neuprozin mito

Patients with stable mild to moderate glaucoma, as assessed perimetrically and tonometrically, will be administered Optigen for 4 months. After this period, Optigen will be discontinued, and patients will be administered Neuprozin mito for an additional 4 months. At baseline, 4 months, and 8 months, the following assessments will be performed: best corrected visual acuity (VA) for both distance and near, IOP, 24-2 visual field (Humphrey Field Analyzer (HFA), Zeiss) with determination of MD, PSD, VFI, GHT; OCT to study the peripapillary retinal nerve fiber layer (RNFL) thickness and the macular ganglion cell complex (GCL-IPL) thickness (Cirrus 6000, Carl Zeiss Meditec); contrast sensitivity using the Spaeth/Richman contrast sensitivity (SPARCS) test (on computer support); quality of life assessment using the Glaucoma Quality of Life 15 (GQL-15) questionnaire; and reading performance using the Italian version of the MNREAD test.

one citicoline tablet per day for 4 months

one fixed combination tablet per 4 months

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Unravelling the effects of Nicotinamide/Pyrroloquinolone Quinone /Citicoline/Homotaurine fixed combination on reading performance in glaucoma
기간: From enrollment to the end of treatment at 8 months

Evaluate whether the intake of NEUPROZIN MITO and OPTIGEN induces changes in reading speed in patients with pharmacologically controlled POAG, and whether there are differences between the two groups at 4 and 8 months.

Reading speed is assessed using the MNREAD App. The MNREAD chart uses standardized sentences consisting of 10 words (60 characters) to determine reading speed across print sizes that decrease logarithmically in 0.1 log-unit steps.

From enrollment to the end of treatment at 8 months
Unravelling the effects of Nicotinamide/Pyrroloquinolone Quinone /Citicoline/Homotaurine fixed combination on contrast sensitivity,
기간: From enrollment to the end of treatment at 8 months

Evaluate whether the intake of NEUPROZIN MITO and OPTIGEN induces changes in contrast sensitivity in patients with pharmacologically controlled POAG, and whether there are differences between the two groups at 4 and 8 months. SPARCS test is a contrast sensitivity test. The range of contrast tested is from 100% to 0.45% (log contrast sensitivity from 0.00 to 2.35), with an approximately 0.15-log-unit decrease between contrast levels.

From enrollment to the end of treatment at 8 months
1. Unravelling the effects of Nicotinamide/Pyrroloquinolone Quinone /Citicoline/Homotaurine fixed combination on quality of life.
기간: From enrollment to the end of treatment at 8 weeks

Evaluate whether the intake of NEUPROZIN MITO and OPTIGEN induces changes in quality of life in patients with pharmacologically controlled POAG, and whether there are differences between the two groups at 4 and 8 months. Assessment of quality of life using the "Glaucoma Quality of Life 15" (GQL-15). This test consists of 15 questions, each assigned a score. The normal score ranges from 0 to 75 points, while higher scores indicate a poorer quality of life.

From enrollment to the end of treatment at 8 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
effects of neuroprotection correlated to glaucoma stage
기간: From enrollment to the end of treatment at eight months

Evaluate potential differences in response in patients with glaucoma at different stages of disease progression.

Determination of the functional stage of the disease based on the mean deviation (MD) obtained through standard automated perimetry (HFA; Carl Zeiss Meditec, Dublin, CA, USA) using the 24-2 SITA-Fast strategy. The visual field defect is classified according to the Hodapp-Parrish-Anderson criteria as mild when MD > -6 dB, moderate when MD ranges from -6 dB to -12 dB, advanced when MD < -12 dB, and severe when MD < -20 dB.

From enrollment to the end of treatment at eight months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 11월 1일

기본 완료 (실제)

2025년 11월 1일

연구 완료 (실제)

2026년 2월 1일

연구 등록 날짜

최초 제출

2026년 9월 22일

QC 기준을 충족하는 최초 제출

2026년 10월 2일

처음 게시됨 (실제)

2026년 10월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 2일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data underlying the results reported in the publication will be available from the corresponding author upon reasonable request, subject to applicable ethical and regulatory requirements.

IPD 공유 기간

Beginning 12 months after publication of the study results and ending 36 months thereafter.

IPD 공유 액세스 기준

Data will be made available upon reasonable request to the corresponding author. Requests will be reviewed by the study investigators and must comply with applicable ethical and regulatory requirements.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .